NCT02677259

Brief Summary

Optimizing in vitro fertilization (IVF) success is more important than ever, in light of new public funding of IVF in Ontario, Canada. In patients undergoing IVF using gonadotropin-releasing hormone (GnRH) analogues, the luteal phase appears to be compromised, which may be a result of controlled-ovarian hyperstimulation, significant fluctuations in hormone levels, the impact of the oocyte retrieval process, or direct compromise of the corpus luteum. Progesterone support is definitely necessary during the luteal phase to facilitate implantation but whether estrogen supplementation is also needed remains unclear. The present study aims to determine whether estradiol support during the luteal phase improves clinical pregnancy rate in patients undergoing IVF.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
506

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started May 2016

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 4, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 9, 2016

Completed
3 months until next milestone

Study Start

First participant enrolled

May 1, 2016

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2018

Completed
Last Updated

February 10, 2016

Status Verified

February 1, 2016

Enrollment Period

2.1 years

First QC Date

February 4, 2016

Last Update Submit

February 9, 2016

Conditions

Keywords

luteal phaseestradiolpregnancy rate

Outcome Measures

Primary Outcomes (1)

  • Clinical Pregnancy

    Presence of fetal heart activity on ultrasound at or beyond 6 weeks gestation.

    Assessed at 6 weeks gestation

Secondary Outcomes (5)

  • Ongoing Pregnancy Rate

    Assessed at 12+1 weeks gestation

  • Implantation Rate

    Assessed at 6 weeks gestation

  • Luteal phase serum estradiol and progesterone concentration

    Performed at oocyte retrieval, 10 days after retrieval, and at the time of serum pregnancy testing, i.e. 17 days after retrieval

  • Miscarriage Rate

    Assessed at 6 - 20 weeks gestation

  • Ectopic Pregnancy Rate

    Assessed at 6 weeks gestation

Study Arms (2)

Estradiol + Standard Luteal Phase Support

EXPERIMENTAL

1. 17-beta estradiol 3 mg PO/PV BID from day of oocyte retrieval until 6 weeks gestation 2. Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation

Drug: 17-beta estradiolDrug: Micronized progesterone

Standard Luteal Phase Support

ACTIVE COMPARATOR

1\. Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation

Drug: Micronized progesterone

Interventions

Also known as: Estrace
Estradiol + Standard Luteal Phase Support
Also known as: Endometrin
Estradiol + Standard Luteal Phase SupportStandard Luteal Phase Support

Eligibility Criteria

Age18 Years - 42 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Indications for IVF/ICSI include male factor, diminished ovarian reserve, tubal factor, ovulatory dysfunction and unexplained infertility.

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (21)

  • Jee BC, Suh CS, Kim SH, Kim YB, Moon SY. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis. Fertil Steril. 2010 Feb;93(2):428-36. doi: 10.1016/j.fertnstert.2009.02.033. Epub 2009 Apr 1.

    PMID: 19342034BACKGROUND
  • Smitz J, Devroey P, Camus M, Deschacht J, Khan I, Staessen C, Van Waesberghe L, Wisanto A, Van Steirteghem AC. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Hum Reprod. 1988 Jul;3(5):585-90. doi: 10.1093/oxfordjournals.humrep.a136750.

    PMID: 3139698BACKGROUND
  • Smith EM, Anthony FW, Gadd SC, Masson GM. Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme. BMJ. 1989 Jun 3;298(6686):1483-6. doi: 10.1136/bmj.298.6686.1483.

    PMID: 2503080BACKGROUND
  • Belaisch-Allart J, De Mouzon J, Lapousterle C, Mayer M. The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Hum Reprod. 1990 Feb;5(2):163-6. doi: 10.1093/oxfordjournals.humrep.a137062.

    PMID: 2108990BACKGROUND
  • van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015 Jul 7;2015(7):CD009154. doi: 10.1002/14651858.CD009154.pub3.

    PMID: 26148507BACKGROUND
  • Fritz MA, Westfahl PK, Graham RL. The effect of luteal phase estrogen antagonism on endometrial development and luteal function in women. J Clin Endocrinol Metab. 1987 Nov;65(5):1006-13. doi: 10.1210/jcem-65-5-1006.

    PMID: 3667871BACKGROUND
  • Goldstein D, Zuckerman H, Harpaz S, Barkai J, Geva A, Gordon S, Shalev E, Schwartz M. Correlation between estradiol and progesterone in cycles with luteal phase deficiency. Fertil Steril. 1982 Mar;37(3):348-54.

    PMID: 7060785BACKGROUND
  • Ganesh A, Goswami S, Chattopadhyay R, Chakraborty C, Chaudhury K, Chakravarty BN. Luteal phase estradiol level: a potential predictive marker for successful pregnancy in in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2009 Apr;91(4):1018-22. doi: 10.1016/j.fertnstert.2008.01.074. Epub 2008 Mar 21.

    PMID: 18359023BACKGROUND
  • Hutchinson-Williams KA, Lunenfeld B, Diamond MP, Lavy G, Boyers SP, DeCherney AH. Human chorionic gonadotropin, estradiol, and progesterone profiles in conception and nonconception cycles in an in vitro fertilization program. Fertil Steril. 1989 Sep;52(3):441-5. doi: 10.1016/s0015-0282(16)60915-9.

    PMID: 2776898BACKGROUND
  • Emperaire JC, Ruffie A, Audebert AJ, Verdaguer S. Early prognosis for IVF pregnancies through plasma oestrogens. Lancet. 1984 Nov 17;2(8412):1151. doi: 10.1016/s0140-6736(84)91577-0. No abstract available.

    PMID: 6150201BACKGROUND
  • Sharara FI, McClamrock HD. Ratio of oestradiol concentration on the day of human chorionic gonadotrophin administration to mid-luteal oestradiol concentration is predictive of in-vitro fertilization outcome. Hum Reprod. 1999 Nov;14(11):2777-82. doi: 10.1093/humrep/14.11.2777.

    PMID: 10548621BACKGROUND
  • Farhi J, Weissman A, Steinfeld Z, Shorer M, Nahum H, Levran D. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril. 2000 Apr;73(4):761-6. doi: 10.1016/s0015-0282(99)00632-9.

    PMID: 10731538BACKGROUND
  • Lukaszuk K, Liss J, Lukaszuk M, Maj B. Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril. 2005 May;83(5):1372-6. doi: 10.1016/j.fertnstert.2004.11.055.

    PMID: 15866571BACKGROUND
  • Var T, Tonguc EA, Doganay M, Gulerman C, Gungor T, Mollamahmutoglu L. A comparison of the effects of three different luteal phase support protocols on in vitro fertilization outcomes: a randomized clinical trial. Fertil Steril. 2011 Mar 1;95(3):985-9. doi: 10.1016/j.fertnstert.2010.06.057. Epub 2010 Aug 2.

    PMID: 20674911BACKGROUND
  • Elgindy EA, El-Haieg DO, Mostafa MI, Shafiek M. Does luteal estradiol supplementation have a role in long agonist cycles? Fertil Steril. 2010 May 1;93(7):2182-8. doi: 10.1016/j.fertnstert.2009.01.066. Epub 2009 Feb 24.

    PMID: 19243745BACKGROUND
  • Gorkemli H, Ak D, Akyurek C, Aktan M, Duman S. Comparison of pregnancy outcomes of progesterone or progesterone + estradiol for luteal phase support in ICSI-ET cycles. Gynecol Obstet Invest. 2004;58(3):140-4. doi: 10.1159/000079115. Epub 2004 Jun 15.

    PMID: 15205566BACKGROUND
  • Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier D, Nulsen J. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertil Steril. 2008 Mar;89(3):554-61. doi: 10.1016/j.fertnstert.2007.04.006. Epub 2007 Aug 2.

    PMID: 17678651BACKGROUND
  • Ceyhan ST, Basaran M, Kemal Duru N, Yilmaz A, Goktolga U, Baser I. Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertil Steril. 2008 Jun;89(6):1827-30. doi: 10.1016/j.fertnstert.2007.08.029. Epub 2007 Dec 11.

    PMID: 18054930BACKGROUND
  • Huang N, Situ B, Chen X, Liu J, Yan P, Kang X, Kong S, Huang M. Meta-analysis of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2015 Feb;103(2):367-73.e5. doi: 10.1016/j.fertnstert.2014.10.029. Epub 2014 Dec 6.

    PMID: 25492682BACKGROUND
  • Fatemi HM, Kolibianakis EM, Camus M, Tournaye H, Donoso P, Papanikolaou E, Devroey P. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Hum Reprod. 2006 Oct;21(10):2628-32. doi: 10.1093/humrep/del117. Epub 2006 Jul 20.

    PMID: 16857887BACKGROUND
  • Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab. 2003 Sep;88(9):4186-92. doi: 10.1210/jc.2002-021953.

    PMID: 12970285BACKGROUND

MeSH Terms

Interventions

EstradiolProgesterone

Intervention Hierarchy (Ancestors)

EstrenesEstranesSteroidsFused-Ring CompoundsPolycyclic CompoundsEstradiol CongenersGonadal Steroid HormonesGonadal HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPregnenedionesPregnenesPregnanesCorpus Luteum HormonesProgesterone Congeners

Central Study Contacts

Evan Taerk, MD,MSc

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. Evan Taerk

Study Record Dates

First Submitted

February 4, 2016

First Posted

February 9, 2016

Study Start

May 1, 2016

Primary Completion

June 1, 2018

Study Completion

June 1, 2018

Last Updated

February 10, 2016

Record last verified: 2016-02